#Review in #MedComm
Efferocytosis in Health and Disease doi.org/10.1002/mco2...
#ApoptoticCellClearance #CD47 #TAMreceptor #efferocytosis #ImmunometabolicRewiring
Latest posts tagged with #CD47 on Bluesky
#Review in #MedComm
Efferocytosis in Health and Disease doi.org/10.1002/mco2...
#ApoptoticCellClearance #CD47 #TAMreceptor #efferocytosis #ImmunometabolicRewiring
#Research
Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera doi.org/10.1186/s435...
#RegulatoryTcells #CD47 #PD_L1 #Immunotherapy #TME #AptamersiRNAchimera
🛡️ Don’t eat me! CD47 therapies are unlocking a new era in cancer immunotherapy. 🧠🧫
#CD47 #CancerTreatment #Immunotherapy #TargetedTherapy #Oncology 🧬
www.marketresearchfuture.com/reports/cd47...
Neuroscientists Unveil Digital 'Translator' for Brain Studies
www.newswise.com/articles/neu...
#CD47 #mesenchymal #fracturerepair #bonefracture #inflammation #translator #studies
Published on March 3, 2025, in Bone Research, a study found that mice lacking CD47 exhibited delayed callus formation and significantly lower bone volume compared to their wild-type counterparts.
#CD47 #fracturerepair
Details: doi.org/10.1038/s41413-025-00409-0
CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer #EBV #CD47 #SIRPα
www.sciencedirect.com/science/arti...
www.cell.com/cell-reports...
"There is also evidence that #CD47 - #SIRPα interactions are important contributors to the maintenance of peripheral tolerance via STAT3 activation (Toledano et al., 2013)."
pmc.ncbi.nlm.nih.gov/articles/PMC...
"The main mechanism of #CD47 ‐mediated immune escape is that it can interact with signal regulatory protein‐alpha ( #SIRPα ) on the surface of macrophages to ultimately blocking phagocytosis."
Another lactate dependent immunosuppressant mechanism, here in Glioblastoma
#GBM #Lactate #CD47 #HistoneLactylation
JCI - Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation www.jci.org/articles/vie...
So proud of the @vigeotx.bsky.social Team on the publication of our First in Human Phase 1 study with VT1021 in #NatureCommunicationsMedicine This paper is a great achievement showing the power of VT1021 treating solid tumors #CD36 #CD47 #VT1021 #NaturePortfolio
rdcu.be/dvUw8